Is myeloperoxidase linked to insulin resistance and metabolic dysfunction?

Myeloperoxidase (MPO) serves as a potent enzymatic driver of oxidative stress and systemic inflammation, playing a significant role in the progression of metabolic dysfunction. Research identifies it not just as a marker, but as a potential mediator of the metabolic shifts that lead to chronic disease.

Clinical evidence and observational data

Human observational studies provide strong evidence for the link between MPO and metabolic impairment, though the strength of evidence varies between current status and future risk:

• Insulin resistance (IR): Cross-sectional data show a robust association between elevated serum MPO and IR. In overweight individuals with a family history of type 2 diabetes (T2DM), MPO predicted IR with a high univariate odds ratio (OR 9.880). In obese women, higher MPO levels significantly correlate with increased HOMA-IR scores.
• Incident Type 2 Diabetes: While MPO is consistently elevated in patients with established T2DM and its complications (such as nephropathy), evidence for MPO as a prospective predictor of incident (new-onset) diabetes is considered plausible but lacks extensive longitudinal confirmation in human cohorts.
• Metabolic Syndrome: MPO levels are significantly higher in patients with metabolic syndrome compared to healthy controls, distinguishing these populations through increased lipid peroxidation and reduced antioxidant defenses.

Mechanistic explanations

MPO contributes to metabolic decay through specific oxidative pathways:

• The MPO/H2O2 Axis: Primarily released by neutrophils and macrophages, MPO uses hydrogen peroxide and chloride to generate hypochlorous acid (HOCl). This potent oxidant initiates systemic lipid peroxidation and activates pro-inflammatory signaling pathways like NF-κB.
• Adipose Tissue Dysfunction: High-fat diets trigger increased MPO expression in adipose tissue. This promotes neutrophil infiltration and adipocyte hypertrophy, leading to a pro-inflammatory environment that directly impairs insulin signaling.
• Causal Insights: Evidence from animal knockout models shows that deleting the MPO gene prevents high-fat diet-induced obesity and insulin resistance, suggesting a causal role in metabolic deterioration.

Bottom line

MPO is a validated oxidative enzyme linked to metabolic dysfunction; its association with insulin resistance is well-supported by human cross-sectional data, while its role in predicting future incident type 2 diabetes is mechanistically plausible but requires further longitudinal validation.